Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.07% |
| 2 | Technology | 14.35% |
| 3 | Financials | 11.23% |
| 4 | Consumer Discretionary | 9.93% |
| 5 | Real Estate | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DRRX
2301
DELISTED
DURECT Corp
DRRX
| $2.09M | ﹤0.01% |
320,789
+16,180
| +5% | +$101K |
|
|
ALYA
2302
DELISTED
Alithya Group Inc Class A Subordinate Voting Shares
ALYA
| $2.09M | ﹤0.01% |
798,176
+16,500
| +2% | +$50K |
|
2303
Escalade
ESCA
$286M
| $2.08M | ﹤0.01% |
181,660
| – | – |
|
2304
Textron
TXT
$15.3B
| $2.08M | ﹤0.01% |
39,300
-578,500
| -94% | -$29.3M |
|
2305
Ohio Valley Banc Corp
OVBC
$217M
| $2.08M | ﹤0.01% |
53,900
-2,766
| -5% | -$104K |
|
|
CTO
2306
CTO Realty Growth
CTO
$826M
| $2.08M | ﹤0.01% |
128,203
+60,417
| +89% | +$989K |
|
2307
Radiant Logistics
RLGT
$410M
| $2.07M | ﹤0.01% |
337,700
-284,900
| -46% | -$1.86M |
|
2308
Fresenius Medical Care
FMS
$12.7B
| $2.07M | ﹤0.01% |
52,600
+24,600
| +88% | +$974K |
|
|
TCFC
2309
DELISTED
The Community Financial Corporation Common Stock
TCFC
| $2.06M | ﹤0.01% |
61,214
+8,701
| +17% | +$266K |
|
|
TTSH
2310
DELISTED
Tile Shop Holdings
TTSH
| $2.06M | ﹤0.01% |
515,600
+95,300
| +23% | +$453K |
|
|
SIOX
2311
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $2.06M | ﹤0.01% |
329,823
+7,435
| +2% | +$56.6K |
|
2312
Nomura Holdings
NMR
$28.9B
| $2.05M | ﹤0.01% |
577,100
+492,700
| +584% | +$1.72M |
|
2313
Vince Holding Corp
VNCE
$80.2M
| $2.05M | ﹤0.01% |
146,747
-1,800
| -1% | -$24.1K |
|
|
FARO
2314
DELISTED
Faro Technologies
FARO
| $2.04M | ﹤0.01% |
38,900
-67,000
| -63% | -$3.39M |
|
2315
Grupo SIMEC
SIM
$4.68B
| $2.04M | ﹤0.01% |
252,195
-305
| -0.1% | -$2.63K |
|
2316
BioLife Solutions
BLFS
$1.71B
| $2.04M | ﹤0.01% |
120,600
-189,300
| -61% | -$3.3M |
|
2317
Lennar Class B
LEN.B
$20.5B
| $2.04M | ﹤0.01% |
55,822
-897
| -2% | -$35.1K |
|
2318
Acadia Realty Trust
AKR
$2.85B
| $2.04M | ﹤0.01% |
74,500
-84,900
| -53% | -$2.38M |
|
|
SEEL
2319
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $2.04M | ﹤0.01% |
242
+118
| +95% | +$1.24M |
|
|
FCCY
2320
DELISTED
1st Constitution Bancorp
FCCY
| $2.03M | ﹤0.01% |
110,100
+6,591
| +6% | +$123K |
|
2321
Protalix BioTherapeutics
PLX
$183M
| $2.03M | ﹤0.01% |
432,653
+30,882
| +8% | +$130K |
|
2322
Vanguard FTSE All-World ex-US ETF
VEU
$70.8B
| $2.03M | ﹤0.01% |
39,800
-28,600
| -42% | -$1.44M |
|
|
CRHM
2323
DELISTED
CRH Medical Corporation
CRHM
| $2.03M | ﹤0.01% |
669,700
+22,500
| +3% | +$64.4K |
|
2324
Varex Imaging
VREX
$780M
| $2.03M | ﹤0.01% |
66,100
+38,800
| +142% | +$1.18M |
|
|
ARQL
2325
DELISTED
Arqule Inc
ARQL
| $2.03M | ﹤0.01% |
+183,983
| New | +$1.28M |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.